Pfizer Inc and BioNTech SE announced on Wednesday that the first participants have been dosed in the US in the Phase 1/2 clinical trial for the BNT162 vaccine programme to prevent COVID-19.
Trending
- Edo killings: Okpebholo visits Kano, vows justice for victims
- Lawmaker to strengthen security in constituency with 1, 000 solar-powered street lights
- FG to shut Lagos’ Independence Bridge for two months
- NUJ @ 70: National secretariat appoints planning committee
- Edo killings: Akpabio condemns act, calls for justice to assuage pains
- Osun threatens to dethrone monarchs over communal clashes
- Kogi Central group calls on Tinubu, stakeholders to intervene In Senate crisis, moves to recall Natasha
- FY 2024: Fidelity Bank records a 210.0% growth in PBT to N385.2bn
